Salute e Benessere

Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.

Alzheimer's disease is a progressive, relentless disease with amyloid beta (Aβ) and tau as hallmarks that is caused by a continuous underlying neurotoxic process that begins before amyloid plaque accumulation and continues after removal.[1],[2],[3] The data show that amyloid-beta protofibrils and tau tangles play roles in the neurodegeneration process,[4],[5],[6] and Leqembi is the only approved treatment that fights Alzheimer's disease in two ways – targeting both amyloid plaque and…
PR Newswire
07/10/2025

UEG Week 2025: Microplastics found to change gut microbiome in first…

The study used stool samples from five healthy volunteers to grow ex vivo gut microbiome cultures. These cultures were then exposed to five common microplastic types – polystyrene, polypropylene, low-density polyethylene, poly(methyl methacrylate) and polyethylene terephthalate – at concentrations reflecting estimated human exposure, as well as higher doses to investigate potential dose-dependent effects. The study used stool samples from five healthy volunteers to grow ex vivo gut microbiome…
PR Newswire
07/10/2025

Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period…

Lupus Nephritis Market Summary Lupus Nephritis Market Summary Discover the new lupus nephritis treatment @Lupus Nephritis Treatment Market Key Factors Driving the Growth of the Lupus Nephritis Market Rising Prevalence of Systemic Lupus Erythematosus and Lupus Nephritis The increasing incidence of SLE, particularly in regions likethe United StatesandSouthern Europe, is contributing to a higher number of lupus nephritis cases. In the US, the lupus nephritis...
PR Newswire
06/10/2025

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its…

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company’s At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares (the “Ordinary Shares”) in the form of American...
Nasdaq GlobeNewswire
06/10/2025

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb)…

New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an injection tracking tool and moreLEQEMBI IQLIK, approved by the U.S. FDA in August 2025, is the first and only anti-amyloid treatment to offer an at-home injection after initial treatment of 18 monthsTOKYO and CAMBRIDGE, Mass., Oct.06, 2025(GLOBE NEWSWIRE) -- Eisai Co., Ltd...
Nasdaq GlobeNewswire
06/10/2025

Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR…

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER FOR SALE OF, OR THE SOLICITATION OF AN OFFER TO BUY, THE SECURITIES REFERRED TO HEREIN IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN OR ANY OTHER...
Nasdaq GlobeNewswire
06/10/2025

EssilorLuxottica: Third-Quarter 2025 Revenue Conference Call Invitation

Third-Quarter 2025 Revenue Conference Call Invitation Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our Third-Quarter 2025 Revenue Conference Call on: Thursday, October 16, 2025, at 6:30 pm CEST Dial-in telephone access:If you wish to dial into the conference call, please pre-register at the following link to receive the personal credentials (Dial-in numbers, Conference ID and User ID): https://grid...
Nasdaq GlobeNewswire
06/10/2025

Pharming Group provides update on previously announced G&A expense reduction…

Leiden, the Netherlands, October 6, 2025:Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restructuring is aligned with our previously announced plan to reduce general and administrative (G&A) expenses to optimize capital allocation across the organization. The restructuring includes a redesign of Pharming’s organizational structure and a 20%...
Nasdaq GlobeNewswire
06/10/2025

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon…

New debt facility extends repayment from Q1 2026 to Q4 2030, lowers interest rate and provides access to additional capital for future business developmentCompany adjusts 2025 financial guidance and provides key business updates Saint-Herblain (France), October 6, 2025– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has entered into a debt facility for up to $500 million in non-dilutive financing with funds managed by Pharmakon...
Nasdaq GlobeNewswire
06/10/2025

By 2035, Advanced Wound Care Market Will Surpass USD 20.6 Billion at 7.7% CAGR…

Key Regional Markets Leading Growth: Key Regional Markets Leading Growth: The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.vantagemarketresearch.com/advanced-wound-care-market-1849/request-sample Free Sample Includes: Technological & Industry Momentum: Why This Matters for Executives & Investors? The Advanced Wound Care (AWC) market is rapidly evolving into a multi-billion-dollar growth driver...
PR Newswire
06/10/2025

NCCN Guidelines Navigator for Breast Cancer Genetic Testing and Treatment Debuts…

"The NCCN Guidelines Navigator enables health care providers to quickly find and understand the best available evidence-based options for treating each individual person," said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "The intuitive flow in the NCCN Guidelines Navigator supports easier treatment decision-making based on the latest evidence and expert-consensus. We are pleased to be able to honor Breast Cancer Awareness Month by making some of our most widely used…
PR Newswire
06/10/2025

Clario and the University of Oxford's NeuroMetrology Lab Advance Parkinson's…

Findings from Professor Antoniades' team demonstrate the high potential of movement analysis in PD research and pave the way for predictive and preventive healthcare. In a recent study, a 3-minute in-office assessment predicted fall risk for Parkinson's patients with 84–92% accuracy up to two years in advance and 78% accuracy up to five years in advance. These predictive capabilities may change how the disease is managed and provide greater opportunity to evaluate therapeutic efficacy in…
PR Newswire
06/10/2025

Halia Therapeutics Strengthens Global Genomics Leadership with Appointment of…

"We are thrilled to welcome Paul to Halia. His proven track record in large-scale genomics initiatives—from the UK's 100,000 Genomes Project to the Emirati Genome Programme—makes him an exceptional addition to our leadership team," said David Bearss, Ph.D., CEO of Halia Therapeutics. "His expertise in translating genomic insights into healthcare solutions directly aligns with our mission to develop transformative medicines based on resilience biology." "We are thrilled…
PR Newswire
06/10/2025

Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic…

- Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action with the potential to significantly improve antitumor effects -- Pre-ESGCT meeting monograph includes preclinical data demonstrating the feasibility of VCN-01 intracranial administration for the potential treatment of brain tumors - ROCKVILLE, Md., Oct.06, 2025(GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a...
Nasdaq GlobeNewswire
06/10/2025

PBC Biomed Appoints Mark McMahan as Chief Commercial Officer

In his new role, McMahan will oversee global commercialization strategies for PBC Biomed’s proprietary technologies, including OsStic® bioadhesive, ARC, and VAPS. He will also lead commercial planning for client products, such as the ReFeel™ nerve repair solution, supporting the company’s expanding portfolio of innovative medical technologies.Paul Burke, Managing Partner at PBC Biomed, commented:“This announcement reflects PBC Biomed’s commitment to advancing our global presence and...
Nasdaq GlobeNewswire
06/10/2025

Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership…

Exclusive collaboration and license agreement for the development and global commercialisation of Arbor’s clinical-stage gene editing programme, ABO-101 for primary hyperoxaluria type 1 (PH1)Multitarget research collaboration and option agreement for Arbor’s innovative gene editing technologies for the development of additional rare liver disease targetsArbor eligible to receive up to $115M in upfront and near-term payments, along with $2B in potential development, regulatory and...
Nasdaq GlobeNewswire
06/10/2025

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair®…

LONDON, UK and REYKJAVIK, ICELAND (OCTOBER 6, 2025)— Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application...
Nasdaq GlobeNewswire
06/10/2025

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic…

Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)Oculis will launch the PIONEER Program, which includes multiple global trials intended to support registrations in AON and NAIONCompany to host conference call and webcast at 8:30 AM ET today Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations...
Nasdaq GlobeNewswire
06/10/2025

COSRX Wraps Up "COSRX Glow Market" Pop-Ups Successfully in Paris & London…

According to COSRX, both pop-ups saw overwhelming engagement, with long queues in Paris and a steady buzz in London, drawing a combined total of nearly 20,000 visitors. In collaboration with Moida K-Beauty, the events were held at the stores inherently located in high-traffic areas popular among beauty-conscious and K-beauty enthusiasts. Across both cities, COSRX combined interactive brand experiences with on-site sales, further enhancing accessibility to its best-selling and newly launched…
PR Newswire
06/10/2025

Final Chance to Glow: COSRX Tops Amazon Prime Big Deal Days with Advanced Snail…

LIMITED Prime Big Deal Days: COSRX Essentials Winning Over CustomersNow available as exclusive Amazon Prime Big Deal Days offers, these Amazon's Choice winners and category No. 1 bestsellers showcase what beauty lovers across Europe can't get enough of. LIMITED Prime Big Deal Days: COSRX Essentials Winning Over CustomersNow available as exclusive Amazon Prime Big Deal Days offers, these Amazon's Choice winners and category No. 1 bestsellers showcase what beauty lovers acrossEuropecan't...
PR Newswire
06/10/2025

Onco3R Therapeutics Announces Completion of First Cohort in Phase 1 Trial of…

Dosing of first cohort in Phase 1 trial of O3R-5671 complete with no adverse findingsOn track for full data read out in the first half of 2026Discovery and preclinical data on O3R-5671 selected for oral presentation at United European Gastroenterology Week 2025Leuven, Belgium. October 6, 2025. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today announced the successful...
Nasdaq GlobeNewswire
06/10/2025

Olympus and W. L. Gore & Associates Enter into International Distribution…

Gore and Olympus bring together talent and technology, and this agreement presents opportunities to elevate the standard of care, as both companies share a history of delivering innovative interventional therapeutic products to improve outcomes for patients. With the addition of the GORE® VIABIL® Biliary Endoprosthesis for endoscopic placement to its existing portfolio of stents designed for the biliary tree, Olympus offers healthcare professionals and their patients a broad range of GI devices.
PR Newswire
06/10/2025

Implantica Successfully Completes MDSAP Recertification Audit

Applications for Canada and Brazil are planned for submission in 2026, following completion of the U.S. Food and Drug Administration (FDA) inspections at Implantica's Malta site and its manufacturing facilities. Applications forCanadaandBrazilare planned for submission in 2026, following completion of the U.S. Food and Drug Administration (FDA) inspections at Implantica'sMaltasite and its manufacturing facilities. Additionally, Implantica has received confirmation from the FDA...
PR Newswire
06/10/2025

FDA Lifts Clinical Hold on NUZ-001

Dr Michael Thurn, Managing Director and CEO, commented: "The FDA's clearance of our IND application marks a significant milestone in our mission to bring NUZ-001 closer to patients living with ALS. This achievement reflects both our unwavering commitment to rigorous scientific and clinical development and the tireless dedication of our team. DrMichael Thurn, Managing Director and CEO, commented: "The FDA's clearance of our IND application marks a significant milestone in our mission…
PR Newswire
06/10/2025
Altri  Comunicati